Details of the Drug
General Information of Drug (ID: DMKI2XC)
Drug Name |
Sulfacytine
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Renoquid; Sulfacitina; Sulfacitine; Sulfacitinum; CL 636; Renoquid (TN); Sulfacitina [INN-Spanish]; Sulfacitinum [INN-Latin]; Sulfacytine (USAN); Sulfacytine [USAN:BAN]; N-Sulfanilyl-l-ethylcytosine; Nl-sulfanilyl-1-ethylcytosine; N(sup 1)-(1-Ethyl-1,2-dihydro-2-oxo-4-pyrimidinyl)sulfanilamide; N(sup1)-(1-Ethyl-1,2-dihydro-2-oxo-4-pyrimidinyl)sulfanilamide; Sulfanilamide, N1-(1-ethyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-(8CI); 1-Ethyl N4-sulfanilylcytosin; 1-Ethyl-N-sulfanilylcytosine; 4-amino-N-(1-ethyl-2-oxo-1,2-dihydropyrimidin-4-yl)benzenesulfonamide; 4-amino-N-(1-ethyl-2-oxopyrimidin-4-yl)benzenesulfonamide
|
||||||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||||||
Therapeutic Class |
Antiinfective Agents
|
||||||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||||||
Structure | |||||||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 294.33 | |||||||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 0.1 | ||||||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 4 | ||||||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 4 | ||||||||||||||||||||||||||
ADMET Property | |||||||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||||||
Repurposed Drugs (RPD) | Click to Jump to the Detailed RPD Information of This Drug | ||||||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||